LENZ THERAPEUTICS INC

Lenz Therapeutics Inc. is a clinical-stage biopharmaceutical company whose lead product candidate, VIZZ (aceclidine), is a pharmaceutical eye drop intended to treat presbyopia. The development of such a drug candidate requires preclinical testing, which standardly involves animal models to assess pharmacology, toxicology, and safety prior to human clinical trials. The company’s regulatory filings with the U.S. Food and Drug Administration, including its Integrated Review for VIZZ, are predicated on data from these required animal studies. This business model is inherently reliant on the commercial exploitation of animals for research and development.

The available evidence does not specify the scale or nature of the animal testing conducted by Lenz Therapeutics. However, the company’s operational focus on bringing a new pharmaceutical entity to market places it within an industry sector where animal testing is a foundational and routine component of the product development pathway. No public commitment to alternative, non-animal testing methods or a cruelty-free development policy was identified in the gathered materials.